| Document |
Document Title |
|
WO/2010/064871A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells including the same. The organic electroluminescent compound provides superior luminous efficiency and excellent color...
|
|
WO/2010/059503A2 |
The present invention relates generally to processes of making (R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodopheny
lamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, intermediates thereof, and a process for making a parti...
|
|
WO/2010/057544A1 |
The invention relates to a method for removing added hydrogen cyanide from ethane dinitrile, characterized in that the gaseous ethane dinitrile comprising hydrogen cyanide is brought into contact with an absorption means.
|
|
WO/2010/058577A1 |
Disclosed is a method for producing an unsaturated aminocarboxylic acid derivative, which is useful as a pharmaceutical raw material, at low cost. Specifically, an unsaturated aminocarboxylic acid derivative is produced by hydrolyzing a...
|
|
WO/2010/054988A2 |
The present invention relates to a process for preparing a cyclic diamine, comprising the reaction of at least one cyclic alkene with a gas mixture (G) comprising dinitrogen monoxide to give at least one cyclic ketone and the subsequent ...
|
|
WO/2010/056877A2 |
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is dir...
|
|
WO/2010/055911A1 |
A compound represented by formula (I) or a salt thereof, which is useful as an agent for treatment or prevention of various epileptic seizures, namely partial seizures and/or generalized seizures. (In the formula, R1, R2 and R3 may be th...
|
|
WO/2010/055005A1 |
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates...
|
|
WO/2010/056452A2 |
Dimeric cyanoacrylate compounds of Formula (I) and Formula (II) having low volatility are provided for absorption of radiation in the UV-A region of the electromagnetic spectrum, which encompasses wavelengths between 320 nm and 400 nm. T...
|
|
WO/2010/052635A1 |
The present invention concerns a compound of formula wherein R represents a hydrogen atom or a C1-2 alkyl or alkoxyl group; each R1, R2 or R3 represents a hydrogen atom or a methyl or ethyl group; and X represents a CHO, COOR4 or CN grou...
|
|
WO/2010/052636A1 |
27 Abstract The present invention concerns the use as perfuming ingredient, for instance to impart odor notes of the floral and/or green type, of a compound of formula 5 wherein R is an ortho, meta or para substituent of the phenyl, and ...
|
|
WO/2010/054032A2 |
Methods and apparatus for facilitating the synthesis of compounds in a batch device are presented. Application of the batch type microfluidic devices to the synthesis of radiolabeled compounds is described. These methods and apparatus en...
|
|
WO/2010/048715A1 |
The invention relates to gemini surfactants of formula IA wherein A is a core derived from an organic polyhydroxy compound; R1 and R2 are each independently a hydrophobic group; and R3 and R4 are each independently a surfactant head grou...
|
|
WO/2010/051103A1 |
A method of quenching fluorescence of a naphthalate polyester that is subjected to UV- radiation in an amount sufficient to cause the naphthalate polyester to reach an excited state and fluoresce, comprising adding to the naphthalate pol...
|
|
WO/2010/046226A1 |
The present invention relates to a method for producing compounds including at least one nitrile function by the hydrocyanation of a compound including at least one non-conjugated unstauration. The invention relates to a method for produ...
|
|
WO/2010/043148A1 |
Disclosed is a 2-cyano-3-(substituted) amino-3-phenyl acrylic ester compound, preparing method and use thereof. The compound，which has the structure of formula (I), has good fungicidal activity, and may be used for preventing and curin...
|
|
WO/2010/044893A1 |
The invention provides the use of a combination of an mTOR inhibitor chsu as deforolimus, and an anti-androgen, such as bicalutamide, in the treatment of prostate cancer.
|
|
WO/2010/044031A1 |
The present invention concerns some nitrile derivatives of formula (I) wherein R represents a methyl or ethyl group; R6 represents a hydrogen atom or a methyl or ethyl group; R1 and R2, taken separately, represent each a hydrogen atom or...
|
|
WO/2010/044405A1 |
Provided is a compound that is useful for the prevention of and as a remedy for diseases attributable to abnormal plasma uric acid levels. The invention pertains to a fused-ring derivative represented by formula (I), and to prodrugs or s...
|
|
WO/2010/040843A2 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, X and Y are defined as cited in the description. The compounds have an immune-modulating action and inhibit or regulate the release of IL-1β and/or TNF-α. They...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/035766A1 |
Provided is a method whereby a triazole derivative having a (1,3-dioxan-5-yl)thio group of improved qualities can be produced at an elevated yield by using an industrially more advantageous operation while reducing impact on the environm...
|
|
WO/2010/032771A1 |
Disclosed is a novel amino acid derivative having excellent analgesic activity. The amino acid derivative is a novel compound which exhibits excellent analgesic activity not only with respect to nociceptive pain model animals, but also w...
|
|
WO/2010/033168A2 |
Compounds are provided according to formula (I), where A, B, W, X', L, R1, R3, R4b, and m' are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of cond...
|
|
WO/2010/027051A1 |
Disclosed is a novel intermediate for producing a substituted isoxazoline compound that is useful as a harmful organism control agent. Specifically disclosed are: a substituted acetophenone compound represented by general formula (1) or ...
|
|
WO/2010/021093A1 |
Provided are a novel asymmetric organic catalyst with which it is possible to realize a high optically-active yield when said catalyst is used in a small amount, and a method for producing a compound using the same. The asymmetric organi...
|
|
WO/2010/018857A1 |
An amide derivative represented by general formula (3) and having excellent pest control activity is produced by reacting a compound represented by general formula (1) with a compound represented by general formula (2). In general formul...
|
|
WO/2010/018714A1 |
Disclosed is an amide derivative having excellent pest control effect, which is represented by general formula (1). In general formula (1), A represents a carbon atom, a nitrogen atom or the like; K represents a non-metal atomic group ne...
|
|
WO/2010/015655A1 |
There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
|
|
WO/2010/016549A1 |
A tricyclic compound having a PPARγ-agonistic activity which is represented by general formula (I) [wherein Z represents a single bond or the like; Y represents a hydrogen atom, an optionally substituted lower alkyl or the like; X repre...
|
|
WO/2010/013567A1 |
Disclosed is a pest control agent having an excellent effect, which contains, as an active ingredient, a compound represented by general formula (1). (In the formula, A represents a carbon atom, a nitrogen atom or the like; K represents...
|
|
WO/2010/013159A1 |
The present invention provides a process for preparing Teriflunomide of formula (I).
|
|
WO/2010/009508A1 |
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
|
|
WO/2010/010113A1 |
The present invention is directed to a process for the manufacture of compounds of formula IV wherein R1 is an amino protecting group, and R2 is hydrogen or C1-10 alkyl, comprising a) reacting a compound of formula Ia, wherein M+ is a ca...
|
|
WO/2010/010174A1 |
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase...
|
|
WO/2010/007253A2 |
A method for preparing the compounds of formula (IV): in which R1, R2, R3 and R4, which may be identical or different, are each a hydrogen atom, a linear or branched (C1-C6) alkyl group, a linear or branched (C1-C6) alkoxy group, a fluor...
|
|
WO/2010/004957A1 |
Disclosed is a novel chiral iridium aqua complex having good storage stability, which can be easily produced. The chiral iridium aqua complex can achieve a high yield and a high stereoselectivity in an asymmetric transfer hydrogenation ...
|
|
WO/2010/004575A2 |
The present patent application relates to an improved process for the preparation of escitalopram, its salts and intermediates. It also relates to a novel crystalline form S of citalopram diol intermediate, process for preparation and it...
|
|
WO/2010/001821A1 |
Disclosed are a compound represented by general formula (I) (wherein R1 and R2 each represents a hydrogen, a lower acyl, a lower alkoxycarbonyl or the like; R3 represents a lower alkyl, a halogenated lower alkyl, a cycloalkyl, a heterocy...
|
|
WO/2009/157418A1 |
Disclosed is a highly safe agent for treating and/or preventing diabetes or the like, which has excellent activity. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (...
|
|
WO/2009/157589A1 |
Disclosed is a process for producing a compound represented by formula (2) [wherein X represents an alkyl group which may be substituted, or the like; R1 represents an alkyl group which may be substituted, or the like; and m represents a...
|
|
WO/2009/157196A1 |
Disclosed is a compound having GPR52 agonist activity and serving as an agent for preventing or treating schizophrenia or the like. Specifically disclosed is a compound represented by formula (I) or a salt thereof. In the formula, A repr...
|
|
WO/2009/153171A1 |
The present invention relates to a process for the hydrocyanation of ethylenically unsaturated organic compounds to give compounds comprising at least one nitrile function. The present invention proposes a process for the hydrocyanation ...
|
|
WO/2009/155362A1 |
Compounds with physiological effects, such as the activation of hematopoietic growth factor receptors, are disclosed. These compounds can be used to treat a variety of conditions, diseases and ailments, including hematopoietic conditions...
|
|
WO/2009/153172A1 |
The present invention relates to a process for the hydrocyanation of ethylenically unsaturated organic compounds to give compounds comprising at least one nitrile function. The present invention proposes a process for the hydrocyanation ...
|
|
WO/2009/149797A1 |
The invention relates to a process for preparing a compound according to formula (I). The invention also relates to useful intermediates in the process.
|
|
WO/2009/150363A2 |
The invention relates to a hydrocyanic acid containing bioresource carbon, and to a method for producing a raw material mainly containing the same by reacting ammonia with methane or methanol optionally in the presence of air and/or oxyg...
|
|
WO/2009/147624A2 |
The present invention relates to a process for preparing Teriflunomide of formula (I).
|
|
WO/2009/147217A1 |
The present invention relates to compounds of formula (I) below in which: - R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, - R2 and R4 represent, independently of ...
|
|
WO/2009/146218A2 |
This invention provides novel compounds comprising the following anti-inflammatory pharmacore Formula (I): wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprisin...
|
